Your browser doesn't support javascript.
loading
Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD.
Toyoda, Hidenori; Fujii, Hideki; Iwaki, Michihiro; Hayashi, Hideki; Oeda, Satoshi; Hyogo, Hideyuki; Kawanaka, Miwa; Morishita, Asahiro; Munekage, Kensuke; Kawata, Kazuhito; Yamamura, Sakura; Sawada, Koji; Maeshiro, Tatsuji; Tobita, Hiroshi; Yoshida, Yuichi; Naito, Masafumi; Araki, Asuka; Arakaki, Shingo; Kawaguchi, Takumi; Noritake, Hidenao; Ono, Masafumi; Masaki, Tsutomu; Yasuda, Satoshi; Tomita, Eiichi; Yoneda, Masato; Kawada, Norifumi; Tokushige, Akihiro; Kamada, Yoshihiro; Takahashi, Hirokazu; Ueda, Shinichiro; Aishima, Shinichi; Sumida, Yoshio; Nakajima, Atsushi; Okanoue, Takeshi.
Afiliación
  • Toyoda H; Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Fujii H; Departments of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Iwaki M; Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Hayashi H; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Oeda S; Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.
  • Hyogo H; Liver Center, Saga University Hospital, Saga, Japan.
  • Kawanaka M; Department of Laboratory Medicine, Saga University Hospital, Saga, Japan.
  • Morishita A; Department of Gastroenterology, JA Hiroshima Kouseiren General Hospital, Hatsukaichi, Japan.
  • Munekage K; Department of General Internal Medicine2, Kawasaki Medical Center, Kawasaki Medical School, Okayama, Japan.
  • Kawata K; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kita-gun, Japan.
  • Yamamura S; Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi, Japan.
  • Sawada K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Maeshiro T; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Tobita H; Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Asahikawa Medical University, Asahikawa, Japan.
  • Yoshida Y; First Department of Internal Medicine, University of the Ryukyus Hospital, Okinawa, Japan.
  • Naito M; Department of Hepatology, Shimane University Hospital, Izumo, Japan.
  • Araki A; Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Suita, Japan.
  • Arakaki S; Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Suita, Japan.
  • Kawaguchi T; Department of Hepatology, Shimane University Hospital, Izumo, Japan.
  • Noritake H; First Department of Internal Medicine, University of the Ryukyus Hospital, Okinawa, Japan.
  • Ono M; Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
  • Masaki T; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Yasuda S; Division of Innovative Medicine for Hepatobiliary & Pancreatology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
  • Tomita E; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kita-gun, Japan.
  • Yoneda M; Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Kawada N; Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.
  • Tokushige A; Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kamada Y; Departments of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Takahashi H; Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyu, Okinawa, Japan.
  • Ueda S; Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Aishima S; Liver Center, Saga University Hospital, Saga, Japan.
  • Sumida Y; Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyu, Okinawa, Japan.
  • Nakajima A; Department of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga, Japan.
  • Okanoue T; Graduate School of Healthcare Management, International University of Healthcare and Welfare, Tokyo, Japan.
Gastro Hep Adv ; 2(8): 1093-1102, 2023.
Article en En | MEDLINE | ID: mdl-39131553
ABSTRACT
Background and

Aims:

Nonalcoholic fatty liver diseases (NAFLD) and nonalcoholic steatohepatitis (NASH) can cause hepatocellular carcinoma (HCC). We examined histological features and reported noninvasive markers/models for stratifying the risk of HCC development in patients with biopsy-proven NAFLD or NASH.

Methods:

A total of 1389 patients who had a histological diagnosis of NAFLD or NASH based on liver biopsy and underwent regular surveillance for HCC were included. The ability to predict HCC development was compared between histological features including liver fibrosis and NAFLD activity score, and noninvasive markers/models including aMAP (age, male, albumin-bilirubin, and platelet) score, FIB-4 (Fibrosis-4) index, and ALBI (albumin-bilirubin) score calculated at the time of biopsy.

Results:

The C index of aMAP score was 0.887, which was consistent with the original report, comparable to FIB-4 index (0.878), and higher than those of ALBI score (0.789), histological liver fibrosis (0.723), and NAFLD activity score (0.589). The hazard ratios for HCC development in the aMAP intermediate and high-risk groups were 21.0 (95% confidence interval [CI], 3.6-402.0) and 110.3 (95% CI, 16.3-2251.4), respectively, in comparison to the aMAP score low-risk group. Those in the FIB-4 index moderate- and high-fibrosis groups were 10.3 (95% CI, 1.7-199.8) and 93.1 (95% CI, 16.3-1773.8), respectively, in comparison to the FIB-4 index mild-fibrosis group. No patients in the aMAP score low-risk group developed HCC during the study period.

Conclusion:

For stratifying the risk of HCC development in patients with biopsy-proven NAFLD or NASH, both aMAP score and FIB-4 index showed high discriminative ability as noninvasive markers, which were superior histological features.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gastro Hep Adv Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gastro Hep Adv Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Países Bajos